Studien

 

Das GestoSYS Konsortium
Das GestoSYS Konsortium ist ein Zusammenschluss von Klinikern, Naturwissenschaftlern und Systembiologen aus verschiedenen Universitätskliniken und Instituten Deutschlands und der Schweiz. Die Kernmitglieder gehören der AG Gestose der DGGG an. Sie arbeiteten seit mehr als einem Jahrzehnt zusammen an verschiedenen wissenschaftlichen Fragestellungen zum Thema Präeklampsie. Ein wissenschaftlicher Schwerpunkt gilt dabei der Entdeckung neuer Krankheitsmarker im Blut, die sich zur Diagnose und Früherkennung der Präeklampsie eignen. Zusammen mit Naturwissenschaftlern und Systembiologen wurde nun ein Projekt ins Leben gerufen, um anhand von Parametern im Blut- und Urin das Krankheitsbild der Präeklampsie in einem Computermodell abzubilden. Ein solches Computermodell kann dazu dienen, die Krankheitsentstehung und den Verlauf besser zu verstehen. Hieraus hofft das Konsortium, Früherkennungsstrategien und ggf. sogar neue Behandlungsoptionen ableiten zu können. Das GestoSYS Konsortium zielt somit darauf ab, Mutter und Kind während der Schwangerschaft sicherer zu überwachen.
 
The GestoSYS consortium
The GestoSYS consortium consists of clinicians, life scientists and system biologists from different University Hospitals and Institutes all over Germany as well as international cooperation partners. The core members are associated to the “AG Gestose” of the German Society of Gynecology and Obstetrics that worked together for more than a decade in various projects. The main focus during the last years was the development of detection and prediction strategies for preeclampsia, a potential life-threatening pregnancy related hypertensive disorder, and related complications by the analysis of blood components using different OMIC as well as conventional approaches. Hence, it has become evident that a variety of biosystems are involved in the pathogenesis of preeclampsia and its variants and that all systems have to be regarded as a whole. The subprojects of each clinical member of the GestoSYS consortium along with their analytical partners are based on each main expertise and research focus. Each principle investigator of the subprojects covers in sum the most important clinical and pathophysiological aspects related to preeclampsia. The aim of the GestoSYS consortium is to model the interaction of known and by now unknown pathways and biosystems involved in the maintenance of physiological pregnancy which are related to preeclampsia and subgroups. In the sense ‘from bench to bed-side’ the data will be used to generate a prediction and disease model and to identify possible pathways for the development of new intervention strategies. In an iterative approach the fundamental aspects of model generation, and validation, and translation into the clinics are implemented in our project. As such the consortium combines all necessary expertise from clinical practice, translational medicine, system biology, proteomics, metabolomics, mathematics, and computer science for an integrative approach to develop new strategies for a better care for women’s and fetal’s health during pregnancy.
 
Members of the GestoSYS consortium
Our research consortium is structured into three clusters:
1) Clinical centers,
2) Omics and laboratory analysis,
3) Computational Systems Biology
 
Cluster Clinical Centers
Aachen
University Hospital of the RWTH
Dept. of Obstetrics
Ulrich Pecks
Pauwelsstraße 30
52074 Aachen
 
Bamberg
Klinikum Bamberg
Dept. of Obstetrics
Burkhard Schauf
Buger Straße 80
96049 Bamberg
 
Berlin
Charité Berlin
Dept. of Obstetrics
Stefan Verlohren
Augustenburger Platz 1
13353 Berlin
 
Duisburg
Klinikum Duisburg
Dept. of Obstetrics
Markus Schmidt
Zu den Rehwiesen 9-11
47055 Duisburg
 
Hannover
Medical School Hannover
Dept. of Obstetrics
Frauke von Versen-Höynck
Carl-Neuberg-Str. 1
30625 Hannover
 
Jena
University of Jena
Dept. of Obstetrics
Dietmar Schlembach
Bachstraße 18
07743 Jena
 
Leipzig
University of Leipzig
Dept. of Obstetrics
Holger Stepan
Susanne Schrey
Liebigstr. 20a
04103 Leipzig
 
Rostock
University of Rostock
Dept. of Obstetrics
Toralf Reimer
Johannes Stubert
Südring 81
18059 Rostock
 
 
Cluster OMICs and anylytical institutes
Charité Campus Berlin-Buch
Experimental and Clinical Research Center (ECRC)
Ralf Dechend
Lindenberger Weg 80
13125 Berlin
 
University of Rostock
Proteome Center
Michael O Glocker
Schillingallee 69
18057 Rostock
 
Charité Campus Berlin-Buch
Max-Delbrueck Center for Molecular Medicine,
Experimental and Clinical Research Center (ECRC)
Florian Herse
Lindenberger Weg 80
13125 Berlin
 
University of Berne
Dept. of Nephrology, Hypertension, and Clinical Pharmacology
Geneviève Escher
Freiburgstr. 10
CH-3010 Berne
 
 
Cluster Computational Systems Biology
Hans-Knöll Institute Jena,
Research Group Systems Biology/Bioinformatics
Reinhard Guthke,
Beutenbergstraße 11a
07745 Jena
 
University of the RWTH
Aachen Institute for Advanced Study in Computational Engineering Sciences (AICES)
Andreas Schuppert Schinkelstraße 2
51368 Aachen
 
 
Concept for commercial or clinical exploitation
The exploitation of the results is four fold: Fist, by increasing our knowledge about possible pathways that are involved in the disease new individualized treatment strategies can be developed. Second, the GestoSYS consortium aims to develop a software tool that is sufficient to be integrated into clinical practice and that can predict PE in first or second trimester of pregnancy. Such a tool is important to appease patients and clinicians. This would be cost beneficial because women can be observed less frequently. Moreover, knowing which woman is at risk of developing PREECLAMPSIA early in pregnancy is important to initiate prevention by aspirin or other yet unidentified drugs. A prediction model would also help to recruit patients into clinical intervention trials. Third, pharmacological intervention in pregnant women must be closely monitored and observed. A disease model would be beneficial for estimating the effect and safety of a pharmacological intervention in pregnant women. Last but not least, understanding alterations during physiological pregnancy is essential for the identification of pathological conditions. As such the clinical exploitation has to be regarded in a whole. Once established the pregnancy model could be used not only for the discrimination of PREECLAMPSIA but also for several other complications such as gestational diabetes, pregnancy cholestasis, and fetal growth restriction. The overall goal is to develop new strategies for a better care for women’s and fetal’s health during pregnancy.

 

 

 

Weitere Studien in Bearbeitung!